New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: croscarmellose sodium gelatin black sw-9007 printing ink lactose magnesium stearate microcrystalline cellulose titanium dioxide water - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: brilliant blue fcf croscarmellose sodium erythrosine gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 2.5 mg - immunosuppressants

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 5 mg - immunosuppressants

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 7.5 mg - immunosuppressants

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 10 mg - immunosuppressants

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 15 mg - immunosuppressants

Malta - English - Medicines Authority

genthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 20 mg - immunosuppressants